Italy’s biotech firm Takis began preclinical trials of five new vaccines that could prove effective against the novel coronavirus.
The five versions of the vaccine each deal with different parts of a protein thought to be critical in the COVID-19 infection.
The results of these early trials are expected in Mid-May, but human trials would not start until autumn 2020, the firm told ANSA.
